R
ecent expert recommendations have supported nonfasting lipid assessment. [1] [2] [3] [4] [5] [6] Practical advantages to using nonfasting measurements include increasing patient convenience because patients avoid separate return visits for laboratory draws and improving hospital and clinic efficiency because the need to organize resources around mass patient influx in the morning for blood work is prevented. 1 Moreover, nonfasting triglycerides and non-high-density lipoprotein cholesterol (HDL-C) levels may improve cardiovascular risk prediction. [7] [8] [9] [10] [11] On the other hand, classification of dyslipidemias was historically derived in fasting samples, and cohort studies and clinical trials have traditionally performed fasting assessments. 12, 13 Ultimately, the choice for fasting or nonfasting lipid assessment may depend on how the lipid profile will be used clinically.
14 If the objective is to make data-driven and guideline-supported decisions with respect to whether a patient qualifies for low-density lipoprotein cholesterol (LDL-C)-lowering therapy or whether an on-treatment LDL-C level is optimal, then clinicians may seek to consider the accuracy of fasting versus nonfasting LDL-C measurements. 15 This may be of increasing relevance to clinicians as practice adapts to greater emphasis on precision in delivery of medical care.
Multiple methods exist for LDL-C assessment, but the Friedewald equation (total cholesterol−HDL-C−triglycerides/5 [in milligrams per deciliter]) has been the de facto clinical standard since the 1970s. 16 The equation was derived in the fasting state and uses a fixed ratio of 5:1 between triglycerides and very lowdensity lipoprotein cholesterol (VLDL-C). With fluctuating triglyceride levels and related variation in the ratio of triglycerides to VLDL-C in the postprandial state, Friedewald and colleagues 16 recognized in their original publication that at lower LDL-C levels, even small errors in VLDL-C estimation may result in significant errors in LDL-C estimation. Indeed, we and others have shown substantial LDL-C underestimation at low LDL-C and high triglycerides levels when applying the Friedewald equation in modern patients. [17] [18] [19] [20] The clinical scenario of low LDL-C and high triglycerides is increasingly common in clinical practice as a result of new, efficacious LDL-lowering therapies and the epidemics of obesity and diabetes mellitus increasing the prevalence of hypertriglyceridemia. Furthermore, VLDL-C metabolism may be altered in the nonfasting state with variable activity of enzymes such as lipoprotein lipase, thereby affecting the triglyceride content of VLDL-C. 21, 22 To address the issue of LDL-C accuracy, direct chemical-based LDL-C assays have been developed but may be affected by fasting status with added expense and have generally not improved on Friedewald estimation. [23] [24] [25] In this context, we previously derived a novel method for LDL-C estimation that uses an adjustable ratio of triglycerides to VLDL-C based on triglycerides and non-HDL-C levels. 20 This method improved LDL-C estimation at low LDL-C levels and is now being adopted by laboratories, including Quest Diagnostics. 26, 27 We and others have speculated that the adaptability of the method may offer an accuracy advantage in nonfasting patients over the fixed Friedewald estimation; however, this has not been formally evaluated to date. This is especially important for high-risk patients with secondary prevention LDL-C goals <70 mg/dL, a common lipid cut point used in clinical guidelines to both initiate and intensify lipid-lowering therapy. 1, 2, 15, [28] [29] [30] We therefore evaluated for the first time the impact of fasting status on LDL-C accuracy estimated with the novel method (LDL-CN) compared with LDL-C estimated from the Friedewald equation (LDL-CF) in a large cross-sectional clinical cohort of >1.5 million US patients. We further evaluated the absolute and percent differences in using the Friedewald and novel equations to estimate LDL-C based on fasting status.
METHODS
The data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results. Study materials are securely housed at Johns Hopkins University and can be made available through remote access after completion of a data use agreement. Interested investigators may visit the VLDL (Very Large Database of Lipids) database ClinicalTrials.gov site and may contact the VLDL study Publications and Presentations Committee. 31 
Clinical Perspective
What Is New?
• In this US cross-sectional analysis, we demonstrate for the first time that the novel, adaptable method of low-density lipoprotein cholesterol (LDL-C) estimation is more accurate in nonfasting samples compared with the Friedewald equation.
• Both absolute and percent errors between novelestimated LDL-C and directly measured LDL-C are smaller and less affected by fasting status compared with Friedewald LDL-C, especially in the estimated LDL-C <70 mg/dL category.
What Are the Clinical Implications?
• In making evidence-based decisions about lipidlowering therapy, clinicians and patients can place greater confidence in LDL-C results from nonfasting samples that are calculated with the novel method of LDL-C estimation compared with the classic Friedewald equation.
• This accuracy is especially important for high-risk patients with secondary LDL-C goals of <70 mg/dL, a common clinical cut point used in international guidelines to initiate and titrate lipid-lowering therapies.
Study Population
This is the first study to use the second harvest of the VLDL study and to evaluate the impact of fasting status on novel LDL-C accuracy. The VLDL study has been described in detail previously. 32 The novel method was derived from the first harvest of VLDL patients; this analysis therefore represents patients who were not included in the derivation cohort for the novel equation. When a patient had >1 lipid profile available, we used the first measurement for each participant. We excluded patients with missing age, sex, and fasting status (fasting or nonfasting) or with incomplete lipid values. Because the original Friedewald equation was designed for patients with triglyceride levels <400 mg/dL, we further excluded participants with triglycerides ≥400 mg/dL. 16 There was no age restriction. Figure I in the online-only Data Supplement illustrates the patient selection process.
A total of 1 545 634 participants met the criteria for analysis, including 959 153 fasting patients and 586 481 nonfasting patients. Our study was declared exempt by the Johns Hopkins Institutional Review Board, which waived the requirement of informed consent because we used only deidentified data routinely collected during clinical lipid determinations. All authors attest to full data access and take responsibility for data integrity and analysis. The VLDL study is registered at http://www.clinicaltrials.gov (NCT01698489).
Lipid Measurements
Patients were deemed as fasting if the clinician-ordered lipid sample called for 10 to 12 hours of no oral intake other than water or medications before sample collection. Vertical Auto Profile (VAP) methodology (VAP Diagnostics Laboratory, Inc, Birmingham, AL), a form of rapid ultracentrifugation, was used to directly measure the cholesterol concentration in LDL (LDL-C D ). In brief, the VAP uses single vertical spin, density gradient ultracentrifugation to directly measure total cholesterol, HDL-C, LDL-C, VLDL-C, and other lipoprotein cholesterol parameters in <1 hour. The VAP methodology has been described in full previously. 32 Triglyceride levels were directly measured with the Abbott ARCHITECT C-8000 system (Abbott Laboratories, Abbott Park, IL). Accuracy of VAP was reviewed yearly by random split-sample comparisons with β quantification at the Washington University in St. Louis Core Laboratory for Clinical Studies. Directly measured triglyceride concentrations were compared with samples from the University of Alabama School of Medicine for quality assessment.
Friedewald-estimated LDL-C (LDL-C F ) was calculated as follows: total cholesterol−HDL-C−triglycerides/5 (in milligrams per deciliter). The novel estimation of LDL-C (LDL-C N ) was calculated as follows: total cholesterol−HDL-C−triglycerides/ adjustable factor. The adjustable factors were derived from our previously reported method whereby triglycerides and non-HDL-C were used to assign 1 of 180 different patientspecific factors to estimate VLDL-C (Table I in the online-only Data Supplement).
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Statistical Analysis
All analyses were conducted separately in the fasting and nonfasting groups. Median LDL-C D values were compared between the 2 groups stratified by clinical guideline cut points for LDL-C: <70, 70 to 99, 100 to 129, 130 to 159, 160 to 189, and ≥190 mg/dL. 15, [28] [29] [30] Distributions in the ratio of triglycerides to VLDL-C based on fasting status were examined. To assess population-level correlation between estimated and directly measured LDL-C based on fasting status, we determined via linear regression (R 2 ) the extent of variation in estimated LDL-C explained by LDL-C D .
Patient-level accuracy between estimated LDL-C (LDL-C F or LDL-C N ) and LDL-C D was compared across the clinical LDL-C cut points and classified by fasting status. Accuracy was expressed as the proportion of directly measured LDL-C falling in the appropriate category of estimated LDL-C (LDL-C F or LDL-C N ) because this reflects how clinicians make decisions. For LDL-C <70 mg/dL, we decided a priori to examine accuracy on the basis of the following triglyceride levels used in our prior studies: <100, 100 to 149, 150 to 199, and 200 to 399 mg/dL. 20 Accuracy between the LDL-C estimation methods was compared with a 2-sample test of proportions. We further evaluated the absolute magnitude of error with each method by assessing the percentage of patients whose estimated LDL-C was <5%, 5% to 9%, 10% to 19%, 20% to 29%, and ≥30% or <5, 5 to 9, 10 to 19, 20 to 29, and ≥30 mg/dL of LDL-C D via ultracentrifugation. Poisson regressions were used to assess the interaction between fasting status and LDL-C method stratified by magnitude of error. All P values reported are 2 sided.
Statistical analysis was performed with Stata (StataCorp), version 11.0.
RESULTS
Population Characteristics
Fasting (n=959 153, 62%) and nonfasting (n=586 481, 38%) participants were similar with respect to selected demographics (Table 1) . Both groups had a median age of ≈55 years and were predominantly women. Directly measured median lipid values were almost identical between the 2 groups except for a 15-mg/dL higher median triglycerides level in nonfasting patients. There were no differences in the median LDL-C D values between fasting and nonfasting patients across the clinical LDL-C categories. Furthermore, when stratifying on the basis of triglycerides levels among participants with LDL-C D <70 mg/dL, median LDL-C D values were almost identical between the 2 groups.
Distribution in the Ratio of Triglycerides to VLDL
The median ratio of triglycerides to VLDL-C was 4.9 (interquartile range, 4.3-5.7) in the fasting group and 5.3 (interquartile range, 4.6-6.2) in the nonfasting group. The 5th and 95th percentiles for the ratio of fasting triglycerides to VLDL-C were 3.6 and 7.2 compared with 3.7 and 8.0 for the ratio of nonfasting triglycerides to VLDL-C.
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Correlation in Estimated Versus Measured LDL-C
When all patients were included, there was excellent correlation between estimated and directly measured LDL-C with both methods, with minimal differences in R 2 values between the fasting and nonfasting samples (Friedewald R 2 =0.98 fasting versus 0.96 nonfasting;
novel R 2 =0.99 fasting versus 0.98 nonfasting). However, Friedewald correlation in participants with LDL-C D <70 mg/dL was reduced, especially in nonfasting patients (R 2 =0.66 for fasting samples versus 0.60 for nonfasting samples) compared with the novel method (R 2 =0.80 for both fasting and nonfasting samples).
Magnitude of Patient-Level Error
Overall, the percent differences between estimated LDL-C and LDL-C D were smaller and, across clinical categories, less affected by fasting status when the novel method was used compared with Friedewald estimation (P<0.001; Table 2 ). In particular, for estimated LDL-C <70 mg/dL, 32% of fasting patients and 44% of nonfasting patients had ≥10% differences between estimated LDL-C and LDL-C D with the Friedewald equation. This is in comparison to 9% and 10% of patients, respectively, who had ≥10% differences between LDL-C N and LDL-C D .
With respect to magnitude of error in mg/dL, a similar overall pattern was observed (Tables 3 and 4 ). In those with LDL-C <70 mg/dL, 19% of fasting and 30% of nonfasting patients had ≥10 mg/dL differences between LDL-C F and LDL-C D (Table 3) . Only 2% to 3% of patients had similar degrees of error with the novel method regardless of fasting status. At triglyceride levels of 200 to 399 mg/dL (Table 4) , 73% of fasting and 81% of nonfasting patients had ≥10 mg/dL differences between LDL-C F and LDL-C D , compared with 25% and 20% of patients, respectively, with LDL-C N .
Accuracy in Clinical Categorization
With both fasting and nonfasting samples, accuracy was higher with the novel method across all LDL-C categories (range, 87%-94%) compared with the Friedewald equation (range, 71%-93%; P≤0.001; Figure, A) . Accuracy decreased as LDL-C decreased for both methods. However, accuracy in LDL-C N was less affected by fasting status, with only ≤2% differences in accuracy between the fasting and nonfasting groups across the clinical LDL-C groups. With estimated LDL-C <70 mg/ dL, the difference in accuracy between the LDL-C N in the fasting (94%) and nonfasting (92%) groups was smaller than for LDL-C F (78% and 71%, respectively). The percentage of patients moving into higher or lower estimated LDL-C groups is provided in Table II in the online-only Data Supplement.
Within the estimated LDL-C <70 mg/dL group, accuracy further decreased as triglyceride levels increased for both fasting and nonfasting samples (Figure, B) , particularly for Friedewald estimation (range, 37%-96%) compared with the novel method (range, 82%-94%). Across the triglycerides categories, nonfasting samples had lower rates of accuracy compared with fasting HDL-C indicates high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; LDL-C D , directly measured low-density lipoprotein cholesterol; LDL-C F , Friedewald-measured low-density lipoprotein cholesterol; and LDL-C N , novel measured low-density lipoprotein cholesterol.
samples for both methods. However, even with triglycerides of 200 to 399 mg/dL in nonfasting patients, LDL-C N <70 mg/dL accuracy was superior to LDL-C F (82% versus 37%; P<0.001).
DISCUSSION
In the first analysis of its kind using a validation sample from the VLDL study, >3000 times larger than the Friedewald et al 16 original derivation data set, we assessed the magnitude of error in LDL-C estimation and accuracy in clinical classification based on fasting status. To the best of our knowledge, no previous study has evaluated the impact of fasting status on novel LDL-C estimation. We found that Friedewald estimation of LDL-C in nonfasting samples leads to greater errors of ≥10% or ≥10 mg/dL and greater misclassification based on standard LDL-C clinical cut points compared with Friedewald estimation in fasting samples, particularly at low LDL-C and high triglycerides. In contrast to Friedewald estimation, fasting status had a relatively minimal effect on LDL-C classification with the novel method, which minimizes error and maintains substantially greater accuracy in clinical classification across the range of LDL-C and triglyceride values.
Comparison With Literature
LDL-C has been of long-standing clinical importance in cardiovascular risk assessment and treatment decision making, as reflected in worldwide guidelines. However, international guidelines remain divided about recommending LDL-C estimation in the fasting state. Although the recent 2016 joint consensus statement from the European Atherosclerosis Society and the European Federation of Clinical Chemistry and Laboratory Medicine favors routine nonfasting lipid evaluation, the 2013 American College of Cardiology/American Heart Association prevention guideline suggests otherwise and instead prefers fasting lipid panels. 1, 15 Guidelines and expert recommendations will continue to evolve. [1] [2] [3] [4] [5] [6] 33 However, there is strong interest in nonfasting lipid assessment, and many patients are having nonfasting lipid profiles. In our data, 38% of patients across the United States had their lipid assessments performed in the nonfasting state. This proportion may increase in response to recent expert recommendations and may already be higher in other regions of the world. LDL-C indicates low-density lipoprotein cholesterol; LDL-C D , directly measured low-density lipoprotein cholesterol; LDL-C F , Friedewald-measured low-density lipoprotein cholesterol; and LDL-C N , novel measured low-density lipoprotein cholesterol.
*Overall, the novel method resulted in more patients in the <10% error group and across clinical categories was less affected by fasting status (P<0.001).
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tion, the European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine statement cited multiple population-based studies that found 8% to 19% increases in triglyceride levels in nonfasting samples with resultant decreases of 4% to 25% in LDL-C F . 7, 12, [34] [35] [36] However, averaging the differences in LDL-C between fasting and nonfasting patients across a population masks trends within particular patient groups. In our study, error in Friedewald estimation within nonfasting samples appeared to increase compared with fasting samples as LDL-C decreased, yet these differences were relatively preserved with the novel method.
Furthermore, data from the Copenhagen City Heat Study constituted a core argument in support of nonfasting lipid assessment in the joint European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine statement. 1, 34 Because there was a minimal difference in R 2 values between directly measured LDL-CD and Friedewald estimated LDL-CF in fasting (R 2 = 0.87) and nonfasting (R 2 = 0.84) patients, the joint committee argued for the use of routine nonfasting samples. 1 However, this was again a population-based assessment, and the problem occurs mainly in the specific setting of low LDL-C and high triglycerides. To this point, we have shown that when patients are isolated at a lower LDL-C cut point (<70 mg/dL), the correlation between estimated and directly measured LDL-C markedly decreases and is affected by fasting status with Friedewald estimation yet remains high with the novel method regardless of fasting status. Although many people in a study like ours may have high LDL-C levels at a given point in time, where differences in LDL-C accuracy between the methods may have little consequence, many of the same patients will eventually be treated to lower LDL-C levels, where such differences then become more important.
Implications for Clinical Care
We submit that the central question concerning Friedewald accuracy in nonfasting patients depends on whether nonfasting LDL-C F misclassifies a significant proportion of patients based on clinical LDL-C cut points because this reflects the way that clinicians and patients make data-driven and guideline-recommended decisions. The European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine statement suggests that minor variations in nonfasting lipid values may reclassify only a few individ- LDL-C indicates low-density lipoprotein cholesterol; LDL-C D , directly measured low-density lipoprotein cholesterol; LDL-C F , Friedewald-measured low-density lipoprotein cholesterol; and LDL-C N , novel measured low-density lipoprotein cholesterol.
*Overall, the novel method resulted in more patients in the <10 mg/dL error group and across clinical categories was less affected by fasting status (P<0.001).
uals. 1 However, given the ≈200 million Americans who undergo lipid testing each year and with treatment guidelines using LDL-C values to initiate and titrate therapies, which LDL-C category an estimated value falls within may have important treatment implications for large numbers of individuals. 37 We have specifically shown that individual, patientlevel misclassification increases substantially with Friedewald estimation using nonfasting samples as LDL-C decreases to <70 mg/dL. In this LDL-C range, there is an overall 7% absolute difference in misclassification rates with nonfasting samples compared with fasting samples. This translates to a misclassification of nearly 1 of every 14 additional patients if a clinician uses the Friedewald method in the nonfasting state, which may erroneously exclude such patients for initiation or intensification of lipid-lowering therapy. This inaccuracy worsens in the setting of hypertriglyceridemia and is in contrast to the novel method, which appears to largely preserve estimated LDL-C accuracy with nonfasting samples. In the range for which the Friedewald equation is most problematic and accuracy is of utmost importance for high-risk patients with secondary prevention goals of LDL-C <70 mg/dL, only 1 of every 50 additional patients may be misclassified into a higher LDL-C group when the novel equation is applied to nonfasting samples.
With respect to absolute error, nearly 10 times as many nonfasting patients with LDL-C F <70 mg/dL had errors ≥10 mg/dL in LDL-C calculation compared with the novel method. This amounts to 1 of every 3 patients when the Friedewald equation is applied. Moreover, with hypertriglyceridemia of 200 to 399 mg/dL at this LDL-C level, nearly 4 times as many nonfasting patients had errors ≥10 mg/dL in LDL-C F . With increased variance in the ratio of triglycerides to VLDL-C in the postprandial state, the novel method therefore better accounts for the range of possible triglyceride levels by adjusting the ratio of triglycerides to VLDL-C.
Even within fasting samples, the novel method lends a greater degree of accuracy. In the Friedewald et al 16 original 1972 study consisting of 448 patients, lipid samples were analyzed in the fasting state to reduce fluctuating triglyceride levels. However, even after controlling for any postprandial triglycerides variation, a large variance still exists in the ratio of triglycerides to VLDL-C. This is an unavoidable byproduct of lipid metabolism. Other factors such as diabetes mellitus and insulin resistance, presence of obesity and metabolic syndrome, and genetic predisposition account for inherent causes of triglycerides variation. 38 Assuming a fixed relationship of 5 across a population between triglycerides and VLDL-C does not account for these issues in individuals, even in the fasting state, which explains the greater precision of the adaptable approach.
We acknowledge that lipoprotein(a) [Lp(a)] values may be elevated and therefore affect the accuracy of LDL-C given that the conventional Friedewald and Centers for Disease Control and Prevention definition of LDL-C incorporates the cholesterol contents of Lp(a) and intermediate-density lipoprotein. Although Lp(a) cholesterol is a relatively small fraction of LDL-C in most individuals, it will consist of a higher fraction in those LDL-C indicates low-density lipoprotein cholesterol; LDL-C D , directly measured low-density lipoprotein cholesterol; LDL-C F , Friedewald-measured low-density lipoprotein cholesterol; and LDL-C N , novel measured low-density lipoprotein cholesterol.
*Overall, the novel method resulted in more patients in the <10 mg/dL error group and across clinical categories was less affected by fasting status (P<0.001) except for triglycerides <100 mg/dL (P=0.115).
with high Lp(a). The novel method of LDL-C estimation is calculated with the standard Friedewald and Centers for Disease Control and Prevention definition of LDL-C, and the estimated portion of VLDL-C is not dependent on Lp(a). Furthermore, Lp(a) appears to be unaffected by fasting status and therefore should be relatively constant between the fasting and nonfasting states.
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Limitations
The relative strengths of our study include its sample size and the generalizability of our results. We have previously shown that the population distributions of total cholesterol, HDL-C, triglycerides, LDL-C F , and non-HDL-C from the VLDL cohort are almost identical to those from the US population-representative NHANES (National Health and Nutritional Examination Survey). 20, 32 Limitations include not knowing the exact time of fasting for each patient despite protocol calling for 10 to 12 hours of fasting before sample collection. However, previous studies have suggested that the timing of fasting has minimal effect on the initial absolute increase in triglycerides concentration and subsequent LDL-C estimation in the postprandial period. 10, 35, 38, 40 The VLDL database furthermore does not report the medications used by each patient at the time of lipid collection. Nevertheless, clinical guidelines continue to support the use of longitudinal LDL-C assessment in either the fasting or nonfasting state regardless of any concomitant lipid-lowering therapy. Although we have age and sex available for patients, 2 factors that may affect triglyceride levels and subsequently the variance in the ratio of triglycerides to VLDL-C, other factors such as insulin resistance, race, and obesity were not available for analysis. We further used the first available lipid sample for patients. Intraindividual variation between sequential samples may affect LDL-C classification. However, our sample size ensured adequate numbers of patients for analysis in each arm of the study.
Conclusion
In a large cross-sectional population, we have shown for the first time that estimated LDL-C accuracy and error are largely preserved with novel adaptable LDL-C estimation regardless of fasting status. This is in contrast to the fixed Friedewald method, for which fasting status may have important clinical implications on estimated LDL-C accuracy. With the recent trend toward nonfasting lipid assessment and with the continued focus on LDL-C in global clinical guidelines, the novel method can provide more precise nonfasting LDL-C estimation, particularly for patients with lower LDL-C and higher triglyceride levels. In addition to stimulating further study, these findings may have immediate relevance to guideline committees, laboratory leadership, clinicians, and patients seeking to make decisions based on the most precise information possible.
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